US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Weight Loss Drugs

1,567.99

-10.0364-0.64%

Number of Gainers:- -

Number of Losers:7

Number of Flat:- -

PE:- -

High:1,590.89

Open:1,579.34

Low:1,558.46

Close:1,578.03

Volume:63.22M

Turnover:5.40B

Market Cap:1.63T

Float Cap:1.57T

Loading ...

Viking Therapeutics Plans USD 200 Million Convertible Senior Notes Offering Due 2032

Viking Therapeutics Announces Proposed Offerings of Common Stock and Convertible Senior Notes

THOMSON REUTERS

Viking Therapeutics, - to Offer $200 Mln Common Stock and $200 Mln Convertible Notes Due 2032

THOMSON REUTERS

Viking Therapeutics, - Proceeds to Fund Vk2735, Vk3019 Clinical Development and General Corporate Purposes

THOMSON REUTERS

Eli Lilly & Co. Stock Underperforms Wednesday When Compared to Competitors

Novo Nordisk A/S Stock (NVO) Closed Down by 3.12% on Sep 23: Key Drivers Unveiled

Novo Nordisk A/S Series B Stock Falls Wednesday, Underperforms Market

Novo Nordisk says CagriSema delivers ‘superior’ weight loss in REIMAGINE 5 trial

BridgeBio Real-World Study Shows Attruby Cuts ATTR-CM Clinical Worsening Risk 34% vs Pfizer’s Tafamidis

Canaccord Genuity Remains a Buy on Viking Therapeutics (VKTX)

What Happens to Your Dividends When Interest Rates Stay Higher for Longer?

The Smart Investor

Novo Nordisk Gets Regulatory Nod in Singapore for Wegovy Treatment of Certain Liver Ailments

MT Newswires Live

Market Chatter: Novo Nordisk Mulls Direct NYSE Listing to Boost US Profile

MT Newswires Live

Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO) and Alcon (ALC)

These 'Moonshot' Biotech Stocks Could Break Out, Morgan Stanley Says. What Must Go Right.

Viking Therapeutics, Inc. : Truist Securities Raises Target Price to $87 from $83

THOMSON REUTERS

Structure Therapeutics CMO Blas Coll Crespo Disposes of USD 124,008 Common Shares

Small U.S. Stocks Close Up; Viking Therapeutics Leads Increases

Aytu BioPharma Q4 Revenue Beats Analyst Estimates on EXXUA Sales

Cboe data shows mixed options sentiment in Novo Nordisk with shares down 0.89%

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/BK4599/news?page=10"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK4599","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","market":"US","secType":"PLATE","nameCN":"Weight Loss Drugs","latestPrice":1567.9943,"timestamp":1790971199999,"preClose":1578.0306,"halted":0,"volume":63219586,"delay":0,"changeRate":-0.00636,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":-10.036377,"latestTime":"10-02 16:00:00 EDT","open":1579.339,"high":1590.8905,"low":1558.4647,"amount":5397830895.209707,"amplitude":0.020548,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1790985600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":9.58996,"peRate":28.239741,"turnoverRate":0.005943,"increases":0,"decrements":7,"flats":0,"marketCap":1628153847712,"floatMarketCap":1570705071680},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","high":1590.8905,"amplitude":0.020548,"preClose":1578.0306,"low":1558.4647,"pbRate":"9.58996","latestPrice":1567.9943,"volume":63219586,"delay":0,"open":1579.339,"prevYearClose":1494.5856,"prevWeekClose":1622.7886,"prevMonthClose":1599.3274,"prevQuarterClose":1599.3274,"fiveDayClose":1622.7886,"twentyDayClose":1648.1235,"sixtyDayClose":1637.6415,"secType":"PLATE","market":"US","turnoverRate":0.005943,"peRate":28.239741,"marketCap":1628153847712,"floatMarketCap":1570705071680,"timestamp":1790971199999,"nameCN":"Weight Loss Drugs"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4599\",,,,undefined,":{"bkCode":"BK4599","up":0,"down":7,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4599\",pageSize:20,pageCount:10,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2669143641","title":"Viking Therapeutics Plans USD 200 Million Convertible Senior Notes Offering Due 2032","url":"https://stock-news.laohu8.com/highlight/detail?id=2669143641","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669143641?lang=en_us&edition=fundamental","pubTime":"2026-09-24 04:33","pubTimestamp":1790195616,"startTime":"0","endTime":"0","summary":"Viking Therapeutics plans USD 200 million convertible senior notes offering due 2032Viking Therapeutics launched a public offering of USD 200 million convertible senior notes due 2032.Underwriters hol","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nNDL8YlXBZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["THNR","BK4599","VKTX","BK4585","OZEM","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669436418","title":"Viking Therapeutics Announces Proposed Offerings of Common Stock and Convertible Senior Notes","url":"https://stock-news.laohu8.com/highlight/detail?id=2669436418","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669436418?lang=en_us&edition=fundamental","pubTime":"2026-09-24 04:33","pubTimestamp":1790195595,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nTUA6JVKDZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4139","VKTX","OZEM","BK4599","BK4585","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669436413","title":"Viking Therapeutics, - to Offer $200 Mln Common Stock and $200 Mln Convertible Notes Due 2032","url":"https://stock-news.laohu8.com/highlight/detail?id=2669436413","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669436413?lang=en_us&edition=fundamental","pubTime":"2026-09-24 04:33","pubTimestamp":1790195595,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nTUA6JVKDZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4585","BK4588","THNR","VKTX","OZEM","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669364904","title":"Viking Therapeutics, - Proceeds to Fund Vk2735, Vk3019 Clinical Development and General Corporate Purposes","url":"https://stock-news.laohu8.com/highlight/detail?id=2669364904","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669364904?lang=en_us&edition=fundamental","pubTime":"2026-09-24 04:33","pubTimestamp":1790195595,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nTUA6JVKDZ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VKTX","THNR","BK4585","OZEM","BK4139","BK4588","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669436230","title":"Eli Lilly & Co. Stock Underperforms Wednesday When Compared to Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2669436230","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669436230?lang=en_us&edition=fundamental","pubTime":"2026-09-24 04:31","pubTimestamp":1790195460,"startTime":"0","endTime":"0","summary":"DJ Eli Lilly & Co. Stock Underperforms Wednesday When Compared To CompetitorsThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Eli Lilly & Co.  slipped 1.64% to $1,150.99 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index  falling 0.75% to 7,706.03 and Dow Jones Industrial Average  falling 0.68% to 51,511.59.The stock's fall snapped a five-day winning streak.Eli Lilly & Co. closed 10.96% short of its 52-week high of $1,292.65, which the company achieved on August 19th.The stock underperformed when compared to some of its competitors Wednesday, as Johnson & Johnson  fell 0.01% to $269.17, Pfizer Inc.  rose 0.90% to $28.18, and AbbVie Inc.  fell 0.05% to $265.08.Trading volume  remained 443,603 below its 50-day average volume of 2.6 M.Data source: Dow Jones Market Data, FactSet. Data compiled September 23, 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FHLC","LU2468319806.SGD","SG9999015986.USD","LU0823434583.USD","IE00B775H168.HKD","IXJ","AGNG","LU1712237335.SGD","SG9999015945.SGD","LU0345770308.USD","LU1691799644.USD","LU1057294990.SGD","SG9999015952.SGD","SG9999013999.USD","IE00B1XK9C88.USD","LU0061475181.USD","LU2211815571.USD","SGXZ81514606.USD","IE00BJJMRY28.SGD","LU1145028129.USD","LU1323610961.USD","IE00BK4W5M84.HKD","LU2112291526.USD","LU0106261372.USD","LU0256863811.USD","LU1917777945.USD","LU2462591350.SGD","LU2106854487.HKD","LU2471134879.HKD","LU1093756168.USD","BK4581","SG9999014880.SGD","LU1988902786.USD","LU0266013472.USD","LU2168564149.EUR","LU2265009873.SGD","LU0058720904.USD","LU0456855351.SGD","LU0316494557.USD","LU0256863902.USD","IE0009355771.USD","LU2237443465.HKD","LU2237443382.USD","HRTS","LU2213496289.HKD","IE00B7KXQ091.USD","LLYX","LU2237443978.SGD","LU1127390331.HKD","SG9999017495.SGD","IE0001KFT4U8.USD","LU0471298694.HKD","LU2471134952.CNY","LU0964807845.USD","ELIL","SG9999018857.SGD","LU2750360997.AUD","LU0289739699.SGD","LU2108987350.USD","SG9999001176.USD","LU1280957306.USD","LU0158827948.USD","LU0672654240.SGD","PPH","SG9999001176.SGD","XLV","LU0097036916.USD","IE00BFSS8Q28.SGD","LU1868836914.USD","LU2552382058.USD","LU0238689110.USD","LU1720051108.HKD","SGXZ31699556.SGD","IE00BKPKM429.USD","LU0198837287.USD","LU0353189680.USD","LU0354030438.USD","LU1551013425.SGD","BK4007","LU0889565916.HKD","IE00B4R5TH58.HKD","LU1069344957.HKD","IHE","LU2023250504.SGD","LU2471134523.USD","LU0786609619.USD","IE00BN29S564.USD","LU2750360641.GBP","LU1868836757.USD","LU0203201768.USD","LU0385154629.USD","LU2360106947.USD","LU2756315664.SGD","IE00BJJMRZ35.SGD","LU2089284900.SGD","LU0079474960.USD","LU2552382215.SGD","LU0158827781.USD","RXL","LU2552382132.HKD","LU0323591593.USD","LU1974910355.USD","SG9999018865.SGD","LU2168564222.USD","LU1623119135.USD","BK4533","MEDX","LU0225283273.USD","GDOC","LU2089283258.USD","ILDR","LU1232071149.USD","LU1979441026.SGD","LU2063271972.USD","LU2746668974.SGD","LLII","LU1804176565.USD","LU0320765992.SGD","LU1814569148.SGD","LU0114720955.EUR","IE00BFTCPJ56.SGD","LU0787776722.HKD","LU1291159041.SGD","IE00BK4W5L77.USD","LU1064131342.USD","LU2023251221.USD","OZEM","LU1023059063.AUD","LLYZ","CURE","LU1868836591.USD","LU2462157665.USD","LU2471134796.USD","LU1035775433.USD","LLY","LU1989771016.USD","LU2361044949.HKD","LU2361045086.USD","SG9999015978.USD","SGXZ51526630.SGD","LU2361044865.SGD","LU0471298777.SGD","SGXZ99366536.SGD","LU2491049909.HKD","LU2602419157.SGD","LU0320765059.SGD","LU1983299246.USD","LU1366192091.USD","BK4599","IE0005OL40V9.USD","LU0210536198.USD","IE0004445015.USD","IYH","LU2028103732.USD","LU0122379950.USD","LU2324357040.USD","LU1548497426.USD","LU0174119429.USD","LU0234572021.USD","LU0109394709.USD","IE00BJLML261.HKD","LU2168563687.JPY","LU0353189763.USD","IE00BJT1NW94.SGD","LU0882574139.USD","SGXZ57979304.SGD","LU2357305700.SGD","LU2237443622.USD","LU1061106388.HKD","BK4588","PJP","LU2756315318.SGD","LU0823416689.USD","TRUH","LU0820561818.USD","IE00BWXC8680.SGD","LU0354030511.USD","LU0432979614.USD","LU2456880835.USD","WDNA","BK4585","LU2237443895.HKD","JDOC","LU0094547139.USD","IE00BFSS7M15.SGD","LU0683600562.USD","BK4534","LU0823434740.USD","LU2237438978.USD","SG9999014914.USD","LU0640476718.USD","FTXH","LU2896262040.SGD","MEDI","VHT","IE00B1BXHZ80.USD","LU2264538146.SGD","LU1629891620.HKD","LU2271345857.HKD","LU2168564065.EUR","LU2461242641.AUD","LU0006306889.USD","IE0004445239.USD","LU0345770993.USD","THNR","LU0417517546.SGD","IE0002141913.USD","LU2236285917.USD","LU0466842654.USD","LU2237443549.SGD","ELIS","IE00B4JS1V06.HKD","LU1868837300.USD","LU0820561909.HKD","IE00B2B36J28.USD","LU0689472784.USD","LU2746668461.USD","TMED","LU1093756325.SGD","SG9999014898.SGD","LU2087625088.SGD","LU2089984988.USD","LU0203202063.USD","IE00BKDWB100.SGD","LU2491050071.SGD","GB00BDT5M118.USD","LU0708995401.HKD","LU2023250330.USD","LU2417539215.USD","LU0133085943.USD","CANC","LU0820562030.AUD","LU2111349929.HKD","BK4516","IE00BJJMRX11.SGD","LU1720051017.SGD","LU2491050154.USD","MHIP","LU1551013342.USD","SG9999014906.USD","LU1267930730.SGD","LU0109391861.USD","LU2168564495.EUR","LU0096364046.USD","LU1868837136.USD","LU0943347566.SGD","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669436112","title":"Novo Nordisk A/S Stock (NVO) Closed Down by 3.12% on Sep 23: Key Drivers Unveiled","url":"https://stock-news.laohu8.com/highlight/detail?id=2669436112","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669436112?lang=en_us&edition=fundamental","pubTime":"2026-09-24 04:15","pubTimestamp":1790194525,"startTime":"0","endTime":"0","summary":"• Novo Nordisk shares dropped following disappointing long-term revenue growth targets.\n• Intensifying competition, patent cliff risks, and market share losses weighed heavily.\n• Technical indicators show sell signals with an RSI of 27.877.","market":"hk","thumbnail":"https://resource.tradingkey.com/uploads/20260204/novo-097495ca9dea48fc8abd9bbb031282c3.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/uploads/20260204/novo-097495ca9dea48fc8abd9bbb031282c3.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262183539-market-movers-nvo-20260923","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","NVOX","IE00BZ1G4Q59.USD","LU0154236417.USD","THNR","NVOH","BK4585","BK4007","BK4588","BK4599","NVO","LU1093756168.USD","NVOC","OZEM","IE00BKVL7J92.USD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669791487","title":"Novo Nordisk A/S Series B Stock Falls Wednesday, Underperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2669791487","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669791487?lang=en_us&edition=fundamental","pubTime":"2026-09-24 00:02","pubTimestamp":1790179320,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Novo Nordisk A/S Series B shed 2.5% to DKK252.25 Wednesday on what proved to be an overall negative trading session for the stock market, with the OMX Nordic 40 Index falling 0.8% to 2,648.31.This was the stock's third consecutive day of losses.The company closed DKK157.70 short of its 52-week high of DKK409.95, which the company achieved on January 23, 2026.Trading volume was 5,754,249, compared to the 50-day average trading volume of 4,611,738.Data source: Dow Jones Market Data, FactSet","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4599","BK4588","LU1093756168.USD","NVOH","OZEM","IE00BZ1G4Q59.USD","THNR","BK4007","LU0154236417.USD","NVO","LU1093756325.SGD","NVOC","NVOX","PPH","IE00BKVL7J92.USD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669826694","title":"Novo Nordisk says CagriSema delivers ‘superior’ weight loss in REIMAGINE 5 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2669826694","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669826694?lang=en_us&edition=fundamental","pubTime":"2026-09-23 22:40","pubTimestamp":1790174414,"startTime":"0","endTime":"0","summary":"Novo Nordisk (NVO) this week announced topline results from the phase 3 REIMAGINE 5 and REDEFINE 9 trials of once-weekly CagriSema, an investigatio...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novo-nordisk-says-cagrisema-delivers-superior-weight-loss-in-reimagine-5-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novo-nordisk-says-cagrisema-delivers-superior-weight-loss-in-reimagine-5-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BZ1G4Q59.USD","NVO","LU0154236417.USD","NVOC","BK4599","LU1093756325.SGD","IE00BKVL7J92.USD","OZEM","NVOH","BK4588","LU1093756168.USD","BK4007","PPH","BK4532","THNR","BK4585","NVOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669483841","title":"BridgeBio Real-World Study Shows Attruby Cuts ATTR-CM Clinical Worsening Risk 34% vs Pfizer’s Tafamidis","url":"https://stock-news.laohu8.com/highlight/detail?id=2669483841","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669483841?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:47","pubTimestamp":1790164058,"startTime":"0","endTime":"0","summary":"BridgeBio real-world study shows Attruby cuts ATTR-CM clinical worsening risk 34% vs Pfizer’s tafamidisBridgeBio reported peer-reviewed real-world study results in Cardiology and Therapy comparing its","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nNDL3KrFk7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OZEM","LU0234572021.USD","LU1883839398.USD","BBIO","BK4592","IE0002270589.USD","BK4007","LU0058720904.USD","IE00BLSP4239.USD","LU0456855351.SGD","LU1894683264.USD","IE00BLSP4452.SGD","BK4139","IE000M9KFDE8.USD","LU1066053197.SGD","BK4599","LU0225284248.USD","IE00B19Z3B42.SGD","PFE","SG9999002232.USD","BK4534","LU0225771236.USD","BK4581","IE00B19Z3581.USD","LU0868494617.USD","IE00B3T34201.USD","LU1057294990.SGD","LU0122379950.USD","LU0306807586.USD","LU0170899867.USD","LU1066051498.USD","SG9999011175.SGD","BK4550","LU0321505439.SGD","BK4533","SG9999001176.SGD","BK4585","IE00BBT3K403.USD","LU0289739699.SGD","LU2596442595.SGD","BK4588","SG9999001176.USD","LU0306806265.USD","SG9999003800.SGD","LU1894683348.USD","SGXZ57979304.SGD","LU0321505868.SGD","BK4568","LU1023059063.AUD","BK4505","SG9999013999.USD","SG9999002224.SGD","LU0985481810.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669648839","title":"Canaccord Genuity Remains a Buy on Viking Therapeutics (VKTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669648839","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669648839?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:16","pubTimestamp":1790162192,"startTime":"0","endTime":"0","summary":"In a report released today, Edward Nash from Canaccord Genuity reiterated a Buy rating on Viking Therapeutics, with a price target of $114.00. Acco...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-remains-a-buy-on-viking-therapeutics-vktx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-remains-a-buy-on-viking-therapeutics-vktx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4139","OZEM","BK4585","VKTX","THNR","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669043011","title":"What Happens to Your Dividends When Interest Rates Stay Higher for Longer?","url":"https://stock-news.laohu8.com/highlight/detail?id=2669043011","media":"The Smart Investor","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669043011?lang=en_us&edition=fundamental","pubTime":"2026-09-23 17:30","pubTimestamp":1790155800,"startTime":"0","endTime":"0","summary":"Discover how higher-for-longer interest rates impact dividend stocks – including banks, REITs, and income investments, and what investors should monitor as borrowing costs stay elevated.","market":"nz","thumbnail":"https://thesmartinvestor.com.sg/wp-content/uploads/2026/09/higher-for-longer-interest-rates-300x200.png","type":0,"news_type":0,"thumbnails":["https://thesmartinvestor.com.sg/wp-content/uploads/2026/09/higher-for-longer-interest-rates-300x200.png"],"rights":{"source":"thesmartinvestor_highlight","url":"https://thesmartinvestor.com.sg/what-happens-to-your-dividends-when-interest-rates-stay-higher-for-longer/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thesmartinvestor.com.sg/what-happens-to-your-dividends-when-interest-rates-stay-higher-for-longer/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thesmartinvestor_highlight","symbols":["LU0823038988.USD","SG9999001069.SGD","D05.SI","SGXZ51708014.SGD","LU0955623706.USD","LU2237957902.USD","LU0165289439.USD","SG9999013460.SGD","LU0882747503.HKD","LU2238330802.EUR","LU2242646821.SGD","SGXZ53341947.SGD","BK4568","LU0868494617.USD","LU0737861269.HKD","LU0985481810.HKD","IE0031814969.USD","IE0003895053.USD","LU0819123356.HKD","LU0011963245.USD","LU0819121731.USD","LU0979878070.USD","LU0877626530.USD","LU0289739699.SGD","LU1363072403.SGD","PFE","LU0210637038.USD","LU1920062954.HKD","OZEM","SG9999009443.AUD","SG9999016042.SGD","AIY.SI","LU0320764755.SGD","LU0588545490.SGD","LU3227948356.SGD","LU0823413587.USD","SGXZ24219693.SGD","SG9999001846.SGD","LU0197773673.USD","LU2152927971.USD","SGXZ91733576.SGD","S68.SI","IE00BVYPNQ40.USD","LU0170899867.USD","SGXZ23024854.USD","SG9999001226.SGD","LU0072462343.USD","LU0577902538.SGD","IE00BGHQDM52.EUR","LU0384037296.USD","LU1048588211.SGD","IE00BLSP4452.SGD","LU1064131342.USD","LU1242518857.USD","LU1242518931.SGD","LU0251144936.SGD","LU0456855351.SGD","LU1497734951.SGD","BK6523","LU0235996351.USD","LU1497733631.SGD","SG9999008742.SGD","LU0251143029.SGD","LU0971096721.USD","LU0058720904.USD","SG9999000459.SGD","LU0205439572.USD","LU0873338254.USD","BK6503","LU0532188223.SGD","C38U.SI","LU1770036033.HKD","LU0188438112.USD","LU0441851309.USD","BK6512","LU0321505439.SGD","LU0348783662.USD","BK6112","LU0577902298.EUR","LU1504937902.USD","LU0856984785.SGD","SG9999002620.SGD","SGXZ70427877.SGD","LU1282649067.USD","IE00BVYPNP33.GBP","IE00B19Z3581.USD","LU0878005551.USD","BK6052","BK6011","SG9999013353.USD","LU0886674414.USD","SG9999001176.SGD","LU1894683348.USD","IE00B3T34201.USD","SG9999007991.SGD","BK6137","SG9999006266.SGD","SGXZ44201846.SGD","LU0588545904.SGD","LU1130305938.SGD","LU1066053197.SGD","LU0831093199.SGD","BK4585","LU0306806265.USD","SG9999014484.SGD","SG9999002562.SGD","LU0096374516.USD","LU0675040207.SGD","LU0823397103.USD","LU0955648018.USD","LU1497733557.USD","SG9999004220.SGD","BK4533","LU0823039010.USD","SG9999001176.USD","LU0557290698.USD","SG9999001127.SGD","LU0321505868.SGD","BK4534","LU1634259391.SGD","IE00BKZH1Z71.USD","IE0002270589.USD","LU2506952097.USD","LU1988902786.USD","LU1883839398.USD","LU2242646235.USD","SG9999003800.SGD","SG9999002406.SGD","LU0543330483.HKD","SG9999011175.SGD","LU0122379950.USD","LU0648948544.HKD","LU0441854154.USD","LU0588545730.USD","LU2506951958.HKD","LU0823417653.USD","SG9999001051.SGD","SG9999005177.SGD","SG9999014302.SGD","IE000M9KFDE8.USD","LU0225771236.USD","LU0192582467.USD","LU0823417737.USD","SG9999002414.USD","SG9999014492.USD","SGXZ27511609.SGD","LU0225284248.USD","LU1282649141.HKD","BK6504","LU1119993845.HKD","LU2264538146.SGD","SG9999004360.SGD","LU0831103253.SGD","LU1057294990.SGD","SG9999001135.SGD","LU2257852520.SGD","LU2293587155.HKD","SGXZ57979304.SGD","IE00B19Z3B42.SGD","LU1839390173.USD","SGXZ44547263.SGD","IE00BBT3K403.USD","LU0345775950.USD","BK4592","LU0197773160.USD","SGXZ43160589.SGD","LU0348766576.USD","SGXZ16066938.SGD","BK6072","LU0950375773.USD","LU2596442595.SGD","LU0348744763.USD","LU0345776255.USD","HK0000107257.USD","LU0234572021.USD","BK4588","LU0672654166.SGD","LU0348783233.USD","S63.SI","BK6518","SG9999001903.USD","LU0577902454.USD","SG9999002679.SGD","LU0417516571.SGD","BK6516","LU0865486749.SGD","SG9999013999.USD","LU0211331839.USD","LU0306807586.USD","LU0348767384.USD","LU0898667661.SGD","LU0577902371.SGD","LU1634259557.SGD","LU0348784397.USD","LU2242652126.USD","LU0048573645.USD","LU2506952170.USD","SG9999002604.SGD","BK4007","LU1023059063.AUD","LU0577902611.USD","LU1282649810.SGD","LU0048597586.USD","LU0326948709.USD","SG9999000475.SGD","OV8.SI","LU0029875118.USD","LU0084288322.USD","LU0261945553.USD","LU0043850808.USD","SG9999013478.USD","SG9999000343.SGD","LU0823413660.USD","LU0261947096.USD","IE00BLSP4239.USD","LU0823397285.USD","SG9999002224.SGD","SG9999003925.USD","LU0061477393.USD","LU0169518387.USD","BK6094","LU0878004406.USD","LU0128522157.USD","LU0630378429.USD","LU0762540952.USD","LU0488056044.USD","LU1956131251.USD","BK4599","LU1522347837.USD","SG9999003826.SGD","SG9999002232.USD","SGXZ58947870.SGD","LU0955669360.SGD","LU1066051498.USD","LU2506951875.HKD","SG9999013486.USD","BK6034","LU2237957811.SGD","LU2401740654.USD","SG9999002950.SGD","BK6033","LU1894683264.USD","BK4550","LU0315178854.USD","BK4581","LU0630378692.HKD","LU1920063259.USD","SG9999003461.SGD","LU1211504680.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669109600","title":"Novo Nordisk Gets Regulatory Nod in Singapore for Wegovy Treatment of Certain Liver Ailments","url":"https://stock-news.laohu8.com/highlight/detail?id=2669109600","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669109600?lang=en_us&edition=fundamental","pubTime":"2026-09-23 16:39","pubTimestamp":1790152792,"startTime":"0","endTime":"0","summary":"Novo Nordisk (NVO) has won approval from Singapore authorities for the use of its weight-loss drug, Wegovy, to treat certain liver diseases, the drugmaker said Wednesday.Wegovy, a once-weekly injectab","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NVOC","BK4007","LU0154236417.USD","OZEM","LU1093756168.USD","NVOX","THNR","BK4599","IE00BZ1G4Q59.USD","BK4585","BK4588","LU1093756325.SGD","BK4532","PPH","NVO","NVOH","IE00BKVL7J92.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669106133","title":"Market Chatter: Novo Nordisk Mulls Direct NYSE Listing to Boost US Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2669106133","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669106133?lang=en_us&edition=fundamental","pubTime":"2026-09-23 16:05","pubTimestamp":1790150726,"startTime":"0","endTime":"0","summary":"Novo Nordisk  signaled it may consider upgrading its New York listing as it looks to raise its profile in the US market, the Financial Times reported Wednesday, citing chief executive Mike Doustdar.Doustdar said he sees potential advantages in listing shares directly on the New York Stock Exchange rather than relying on American depositary receipts, though the company is not actively pursuing the move, according to the FT.The US accounts for more than half of Novo's revenue and most of its sales of diabetes and obesity treatments, according to the report.Novo Nordisk did not immediately respond to MT Newswires' request for comment.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OZEM","BK4588","NVOH","NVOX","PPH","BK4599","BK4532","IE00BKVL7J92.USD","LU0154236417.USD","BK4007","NVO","LU1093756325.SGD","NVOC","BK4585","THNR","IE00BZ1G4Q59.USD","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669386103","title":"Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO) and Alcon (ALC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669386103","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669386103?lang=en_us&edition=fundamental","pubTime":"2026-09-23 14:50","pubTimestamp":1790146217,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Novo Nordisk (NVO) and Alcon (ALC). Novo Nordisk (...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-novo-nordisk-nvo-and-alcon-alc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-novo-nordisk-nvo-and-alcon-alc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0154236417.USD","BK4532","LU1093756168.USD","LU1093756325.SGD","NVOH","PPH","ALC","IE00BKVL7J92.USD","NVO","NVOC","BK4007","THNR","BK4534","LU2265009873.SGD","BK4599","BK4198","BK4588","LU1804176565.USD","NVOX","BK4585","IE00BZ1G4Q59.USD","OZEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669177094","title":"These 'Moonshot' Biotech Stocks Could Break Out, Morgan Stanley Says. What Must Go Right.","url":"https://stock-news.laohu8.com/highlight/detail?id=2669177094","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669177094?lang=en_us&edition=fundamental","pubTime":"2026-09-23 13:45","pubTimestamp":1790142300,"startTime":"0","endTime":"0","summary":"From speculation over mergers and acquisitions to the hype surrounding clinical readouts, it seems biotechnology stocks are all the rage this year.The iShares Biotechnology exchange-traded fund has ri","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0006306889.USD","LU2357305700.SGD","LU1244550494.USD","LU1244550221.USD","BK4548","ARWR","LU1548497426.USD","LU1791710582.SGD","MS","LU1988902786.USD","VKTX","BK4551","LU1732800096.USD","FMED","BK4599","BK4585","LU1720051017.SGD","LU0098860793.USD","THNR","IE00B775SV38.USD","LU0109394709.USD","LU0210528500.USD","BK4501","MRNY","WDNA","LU0158827948.USD","BK4568","KBWB","ARGX","BK4534","IE00B3S45H60.SGD","IBB","MRNA","OZEM","IDNA","BK4532","MRNX","XBI","LU2347655156.SGD","LGHT","IE00BKVL7J92.USD","LU1074936037.SGD","LU1989772840.SGD","IAI","IE00B4R5TH58.HKD","BK4504","GNOM","LU0795875169.SGD","LU0234570918.USD","TBXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669744631","title":"Viking Therapeutics, Inc. : Truist Securities Raises Target Price to $87 from $83","url":"https://stock-news.laohu8.com/highlight/detail?id=2669744631","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669744631?lang=en_us&edition=fundamental","pubTime":"2026-09-23 11:44","pubTimestamp":1790135082,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nFWN45F00Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4588","BK4139","BK4599","OZEM","THNR","VKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669203171","title":"Structure Therapeutics CMO Blas Coll Crespo Disposes of USD 124,008 Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2669203171","media":"Reuters","labels":["executive","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669203171?lang=en_us&edition=fundamental","pubTime":"2026-09-23 06:00","pubTimestamp":1790114427,"startTime":"0","endTime":"0","summary":"Structure Therapeutics CMO Blas Coll Crespo disposes of USD 124,008 common sharesStructure Therapeutics Chief Medical Officer Blas Coll Crespo cut his ordinary share stake to 258,228 shares.Disposed o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDL1GxjGX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Structure Therapeutics CMO Blas Coll Crespo Disposes of USD 124,008 Common Shares","news_tag":"executive,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4599","GPCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669122697","title":"Small U.S. Stocks Close Up; Viking Therapeutics Leads Increases","url":"https://stock-news.laohu8.com/highlight/detail?id=2669122697","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669122697?lang=en_us&edition=fundamental","pubTime":"2026-09-23 04:21","pubTimestamp":1790108460,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of small-cap companies added Tuesday, as the Russell 2000 Index gained 0.5%, and the S&P Small Cap 600 Index was up 0.3%.Among companies with a market value of $1 billion to $6.7 billion, Viking Therapeutics Inc. was the best performer during the session, surging 36%, followed by Maze Therapeutics Inc., which surged 27%. Butterfly Network Inc. shares surged 22%, Surgery Partners Inc. jumped 16%, and shares of Innodata Inc. surged 15%.Xanadu Quantum Technologies Ltd. was the biggest laggard, dropping 22%, followed by shares of Celldex Therapeutics Inc., which dropped 12%. Shares of Goosehead Insurance Inc. Cl A dropped 11%, Xtend AI Robotics Inc. shares tumbled 11%, and Atlas Energy Solutions Inc. tumbled 9.6%.Major U.S. stock indexes closed mixed Tuesday as the Nasdaq Composite Index increased 0.5%. Meanwhile, the S&P 500 Index was flat, and the Dow Jones Industrial Average dropped 0.4%.Data source: Dow Jones Ma","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","OZEM","VKTX","BK4139","BK4599","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669577122","title":"Aytu BioPharma Q4 Revenue Beats Analyst Estimates on EXXUA Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2669577122","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669577122?lang=en_us&edition=fundamental","pubTime":"2026-09-23 04:17","pubTimestamp":1790108275,"startTime":"0","endTime":"0","summary":"Aytu BioPharma Q4 revenue beats analyst estimates on EXXUA salesOverviewUS pharmaceutical firm's fiscal Q4 revenue rose 6.4%, beating analyst expectationsCompany reported near break-even net loss for ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nL1N45E0WU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","IE00B2B36J28.USD","IE00B4R5TH58.HKD","BK4534","LU0889565916.HKD","LU2468319806.SGD","LU2112291526.USD","BBH","LU1571399168.USD","LU0320765992.SGD","IE00BFTCPJ56.SGD","AMGN","AYTU","PBE","BK4585","LU1983299246.USD","SG9999001440.SGD","IBB","LU0289739699.SGD","IE0002141913.USD","IE00BJJMRZ35.SGD","IBBQ","TBXU","LU0868494617.USD","LU1057294990.SGD","LU2089984988.USD","LU0058720904.USD","LU0109394709.USD","LU0122379950.USD","BK4533","PJP","LU1061106388.HKD","LU2242646821.SGD","BK4007","IE00BJT1NW94.SGD","BIB","BK4581","BK4599","BK4588","BK4139","LU1023059063.AUD","IE0009355771.USD","LU2242652126.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669126717","title":"Cboe data shows mixed options sentiment in Novo Nordisk with shares down 0.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669126717","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669126717?lang=en_us&edition=fundamental","pubTime":"2026-09-23 01:15","pubTimestamp":1790097314,"startTime":"0","endTime":"0","summary":"Cboe data shows mixed options sentiment in Novo Nordisk (NVO), with shares down 36c near $39.45. Options volume running well above average with 73k...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cboe-data-shows-mixed-options-sentiment-in-novo-nordisk-with-shares-down-0-89-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cboe-data-shows-mixed-options-sentiment-in-novo-nordisk-with-shares-down-0-89-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BKVL7J92.USD","BK4588","LU1093756325.SGD","NVOC","IE00BZ1G4Q59.USD","NVOX","BK4585","PPH","THNR","BK4532","NVOH","BK4007","OZEM","NVO","LU1093756168.USD","BK4599","LU0154236417.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":15,"pageCount":10,"totalSize":295,"code":"91000000","status":"200"}]}}